🇺🇸·23h agoIndustry
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Publisher
M
Merck & Co. (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
Aspen Pharmacare·1d ago
Aspen Australia participates in the 2026 APP Conference
Otsuka Pharmaceutical·1d ago
Otsuka Pharmaceutical Receives Judges' Special Award at MAFF's 10th Shokuiku Activity Awards "MoguMogu Town" App Recognized for Promoting Food and Nutrition Education
Santen Pharmaceutical·1d ago
Santen China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Products in the Chinese Mainland
Natco Pharma·1d ago